162 related articles for article (PubMed ID: 22868969)
1. Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene.
Sloma I; Imren S; Beer PA; Zhao Y; Lecault V; Leung D; Raghuram K; Brimacombe C; Lambie K; Piret J; Hansen C; Humphries RK; Eaves CJ
Leukemia; 2013 Jan; 27(1):159-69. PubMed ID: 22868969
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
3. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.
Beer PA; Knapp DJ; Miller PH; Kannan N; Sloma I; Heel K; Babovic S; Bulaeva E; Rabu G; Terry J; Druker BJ; Loriaux MM; Loeb KR; Radich JP; Erber WN; Eaves CJ
Blood; 2015 Jan; 125(3):504-15. PubMed ID: 25370416
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of HOXB4 and NUP98-HOXA10hd on hematopoietic repopulating cells in a nonhuman primate model.
Watts KL; Zhang X; Beard BC; Chiu SY; Trobridge GD; Humphries RK; Kiem HP
Hum Gene Ther; 2011 Dec; 22(12):1475-82. PubMed ID: 21787196
[TBL] [Abstract][Full Text] [Related]
6. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
7. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia.
Sloma I; Beer PA; Saw KM; Chan M; Leung D; Raghuram K; Brimacombe C; Johnston B; Lambie K; Forrest D; Jiang X; Eaves CJ
Exp Hematol; 2013 Oct; 41(10):837-47. PubMed ID: 23851302
[TBL] [Abstract][Full Text] [Related]
9. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
[TBL] [Abstract][Full Text] [Related]
10. Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID mice.
Holyoake TL; Horrocks C; Thomas T; Eaves CJ; Eaves AC
Cytotherapy; 2000; 2(6):411-21. PubMed ID: 12044221
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.
Jiang X; Stuible M; Chalandon Y; Li A; Chan WY; Eisterer W; Krystal G; Eaves A; Eaves C
Blood; 2003 Oct; 102(8):2976-84. PubMed ID: 12829595
[TBL] [Abstract][Full Text] [Related]
13. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
[TBL] [Abstract][Full Text] [Related]
14. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.
Holyoake T; Jiang X; Eaves C; Eaves A
Blood; 1999 Sep; 94(6):2056-64. PubMed ID: 10477735
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo.
Buske C; Feuring-Buske M; Antonchuk J; Rosten P; Hogge DE; Eaves CJ; Humphries RK
Blood; 2001 Apr; 97(8):2286-92. PubMed ID: 11290589
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells.
Kobari L; Pflumio F; Giarratana M; Li X; Titeux M; Izac B; Leteurtre F; Coulombel L; Douay L
Exp Hematol; 2000 Dec; 28(12):1470-80. PubMed ID: 11146169
[TBL] [Abstract][Full Text] [Related]
17. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
18. HOX decoy peptide enhances the ex vivo expansion of human umbilical cord blood CD34+ hematopoietic stem cells/hematopoietic progenitor cells.
Tanaka H; Matsumura I; Itoh K; Hatsuyama A; Shikamura M; Satoh Y; Heike T; Nakahata T; Kanakura Y
Stem Cells; 2006 Nov; 24(11):2592-602. PubMed ID: 17071861
[TBL] [Abstract][Full Text] [Related]
19. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0).
Glimm H; Oh IH; Eaves CJ
Blood; 2000 Dec; 96(13):4185-93. PubMed ID: 11110690
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
